Pro-Inflammatory Cytokines, IFNγ and TNFα, Influence Immune Properties of Human Bone Marrow and Wharton Jelly Mesenchymal Stem Cells Differentially
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Wharton's jelly derived stem cells (WJMSCs) are gaining attention as a possible clinical alternative to bone marrow derived mesenchymal stem cells (BMMSCs) owing to better accessibility, higher expansion potential and low immunogenicity. Usage of allogenic mesenchymal stem cells (MSC) could be permissible in vivo only if they retain their immune properties in an inflammatory setting. Thus the focus of this study is to understand and compare the immune properties of BMMSCs and WJMSCs primed with key pro-inflammatory cytokines, Interferon-gamma (IFNgamma) and Tumor Necrosis Factor-alpha (TNFalpha). METHODOLOGY/PRINCIPAL FINDINGS: Initially the effect of priming on MSC mediated suppression of alloantigen and mitogen induced lymphoproliferation was evaluated in vitro. Treatment with IFNgamma or TNFalpha, did not ablate the immune-suppression caused by both the MSCs. Extent of immune-suppression was more with WJMSCs than BMMSCs in both the cases. Surprisingly, priming BMMSCs enhanced suppression of mitogen driven lymphoproliferation only; whereas IFNgamma primed WJMSCs were better suppressors of MLRs. Further, kinetic analysis of cytokine profiles in co-cultures of primed/unprimed MSCs and Phytohematoagglutinin (PHA) activated lymphocytes was evaluated. Results indicated a decrease in levels of pro-inflammatory cytokines. Interestingly, a change in kinetics and thresholds of Interleukin-2 (IL-2) secretion was observed only with BMMSCs. Analysis of activation markers on PHA-stimulated lymphocytes indicated different expression patterns in co-cultures of primed/unprimed WJMSCs and BMMSCs. Strikingly, co-culture with WJMSCs resulted in an early activation of a negative co-stimulatory molecule, CTLA4, which was not evident with BMMSCs. A screen for immune suppressive factors in primed/unprimed WJMSCs and BMMSCs indicated inherent differences in IFNgamma inducible Indoleamine 2, 3-dioxygenase (IDO) activity, Hepatocyte growth factor (HGF) and Prostaglandin E-2 (PGE2) levels which could possibly influence the mechanism of immune-modulation. CONCLUSION/SIGNIFICANCE: This study demonstrates that inflammation affects the immune properties of MSCs distinctly. Importantly different tissue derived MSCs could utilize unique mechanisms of immune-modulation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“The initial plating densities and seeding densities for propagation was as previously described [37,38].”
MethodDominici, M., Le Blanc, K., Mueller, I., Slaper-Cortenbach, I., Marini, F. C., Krause, D. S., Deans, R. J., Keating, A., Prockop, D. J., & Horwitz, E. M. (2006) · Cytotherapy · doi:10.1080/14653240600855905 · Cited by 17,766
Human mesenchymal stem cells modulate allogeneic immune cell responses
Aggarwal, S., & Pittenger, M. F. (2005) · Blood · doi:10.1182/blood-2004-04-1559 · Cited by 4,511
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Mesenchymal stem cells reside in virtually all post-natal organs and tissues
Meirelles, L. D. S., Chagastelles, P. C., & Nardi, N. B. (2006) · Journal of Cell Science · doi:10.1242/jcs.02932 · Cited by 2,485
Chamberlain, G., Fox, J., Ashton, B., & Middleton, J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0197 · Cited by 2,381
Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntosh, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., et al. (2002) · Experimental Hematology · doi:10.1016/s0301-472x(01)00769-x · Cited by 2,295
Ren, G., Zhang, L., Zhao, X., Xu, G., Zhang, Y., Roberts, A. I., Zhao, R. C., & Shi, Y. (2008) · Cell Stem Cell · doi:10.1016/j.stem.2007.11.014 · Cited by 2,101
Phinney, D. G., & Prockop, D. J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0637 · Cited by 1,908
Human mesenchymal stem cells modulate B-cell functions
Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Risso, M., Gualandi, F., Mancardi, G. L., Pistoia, V., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2657 · Cited by 1,767
Cited by
Priming approaches to improve the efficacy of mesenchymal stromal cell-based therapies
Noronha, N. D. C., Mizukami, A., Caliári-Oliveira, C., Cominal, J. G., Rocha, J. L. M., Covas, D. T., Swiech, K., & Malmegrim, K. C. R. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1224-y · Cited by 623
“TNF-α priming TNF-α priming promotes upregulation of immunoregulatory factors on MSC, such as PGE2, IDO, and HGF, however much less pronounced compared with IFN-γ priming [29].”
ResultUmbilical cord-derived mesenchymal stem cells: Their advantages and potential clinical utility
Nagamura-Inoue, T. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i2.195 · Cited by 476
YlÖstalo, J. H., Bartosh, T. J., Coble, K., & Prockop, D. J. (2012) · STEM CELLS · doi:10.1002/stem.1191 · Cited by 427
Vasandan, A. B., Jahnavi, S., Shashank, C., Prasad, P., Kumar, A., & Prasanna, S. J. (2016) · Scientific Reports · doi:10.1038/srep38308 · Cited by 406
Self-citationImmunoregulation by Mesenchymal Stem Cells: Biological Aspects and Clinical Applications
Castro-Manrreza, M. E., & Montesinos, J. J. (2015) · Journal of Immunology Research · doi:10.1155/2015/394917 · Cited by 399
Mesenchymal stromal cell ‘licensing’: a multistep process
Krampera, M. (2011) · Leukemia · doi:10.1038/leu.2011.108 · Cited by 358
The stem cell secretome and its role in brain repair
Drago, D., Cossetti, C., Iraci, N., Gaude, E., Musco, G., Bachi, A., & Pluchino, S. (2013) · Biochimie · doi:10.1016/j.biochi.2013.06.020 · Cited by 348
Kim, D.-W., Staples, M., Shinozuka, K., Pantcheva, P., Kang, S.-D., & Borlongan, C. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140611692 · Cited by 340
El Omar, R., Beroud, J., Stoltz, J.-F., Menu, P., Velot, E., & Decot, V. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0664 · Cited by 330
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., Vega, B., Schneider, J., & Vizoso, F. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03600-0 · Cited by 313
Mattar, P., & Bieback, K. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00560 · Cited by 300
Najar, M., Raicevic, G., Boufker, H. I., Kazan, H. F., Bruyn, C. D., Meuleman, N., Bron, D., Toungouz, M., & Lagneaux, L. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.06.006 · Cited by 275
Ribeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., Santos, F., Henriques, A., Grãos, M., Cardoso, C. M. P., et al. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt336 · Cited by 266
The therapeutic potential of the mesenchymal stem cell secretome in ischaemic stroke
Cunningham, C. J., Redondo-Castro, E., & Allan, S. M. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18776802 · Cited by 242
CD106 Identifies a Subpopulation of Mesenchymal Stem Cells with Unique Immunomodulatory Properties
Yang, Z. X., Han, Z.-B., Ji, Y. R., Wang, Y. W., Liang, L., Chi, Y., Yang, S. G., Li, L. N., Luo, W. F., Li, J. P., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0059354 · Cited by 225
Mougiakakos, D., Jitschin, R., Johansson, C. C., Okita, R., Kiessling, R., & Le Blanc, K. (2011) · Blood · doi:10.1182/blood-2010-12-324038 · Cited by 205
Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells
Chen, P.-M., Yen, M.-L., Liu, K.-J., Sytwu, H.-K., & Yen, B.-L. (2011) · Journal of Biomedical Science · doi:10.1186/1423-0127-18-49 · Cited by 180
“Interestingly, a number of reports have demonstrated that in in vitro systems, pretreatment of BMMSCs and F-MSCs with the pro-inflammatory cytokine IFN-g actually enhances their immunomodulation rather than decreases it [40,59,95].”
BackgroundMesenchymal stem cells in preclinical cancer cytotherapy: a systematic review
Christodoulou, I., Goulielmaki, M., Devetzi, M., Panagiotidis, M., Koliakos, G., & Zoumpourlis, V. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-1078-8 · Cited by 122
Li, M., Jiang, Y., Hou, Q., Zhao, Y., Zhong, L., & Fu, X. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-02822-2 · Cited by 119
Todeschi, M. R., El Backly, R., Capelli, C., Daga, A., Patrone, E., Introna, M., Cancedda, R., & Mastrogiacomo, M. (2015) · Stem Cells and Development · doi:10.1089/scd.2014.0490 · Cited by 103
Abbasi-Kangevari, M., Ghamari, S.-H., Safaeinejad, F., Bahrami, S., & Niknejad, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00238 · Cited by 79
Laurent, C. P., Vaquette, C., Liu, X., Schmitt, J.-F., & Rahouadj, R. (2018) · Journal of Biomaterials Applications · doi:10.1177/0885328218757064 · Cited by 49
Srinivasan, A., Sathiyanathan, P., Yin, L., Liu, T. M., Lam, A., Ravikumar, M., Smith, R. A. A., Loh, H. P., Zhang, Y., Ling, L., et al. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2021.11.009 · Cited by 44
Bárcia, R. N., Santos, J. M., Teixeira, M., Filipe, M., Pereira, A. R. S., Ministro, A., Água-Doce, A., Carvalheiro, M., Gaspar, M. M., Miranda, J. P., et al. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2016.11.008 · Cited by 40
Bobyleva, P. I., Andreeva, E. R., Gornostaeva, A. N., & Buravkova, L. B. (2016) · Stem Cells International · doi:10.1155/2016/4726267 · Cited by 21
“For the manifestation of immunosuppression, MSCs have to be activated (primed) [10–13].”
Influential
Metadata
- Authors
- Prasanna, S. J., Gopalakrishnan, D., Shankar, S. R., & Vasandan, A. B.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2010-02-02
- Volume
- 5
- Issue
- 2
- Pages
- e9016
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2061172918
- Cited by
- 467
- References
- 59
- FWCI
- 11.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.